2. Apoptosis
  3. Ferroptosis Apoptosis
  4. Dexrazoxane

Dexrazoxane  (Synonyms: ICRF-187; ADR-529; NSC-169780)

Cat. No.: HY-B0581 Purity: 99.88%
SDS COA Handling Instructions

Molarity Calculator

Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .

For research use only. We do not sell to patients.

Dexrazoxane Chemical Structure

Dexrazoxane Chemical Structure

CAS No. : 24584-09-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
25 mg USD 50 In-stock
50 mg USD 80 In-stock
100 mg USD 130 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Dexrazoxane:

Dexrazoxane Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells[1] [2] [3] [4] [5] [6].

Cellular Effect
Cell Line Type Value Description References
HL-60 IC50
18 μM
Compound: DEX; ICRF-187
Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay
Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay
[PMID: 33750129]
In Vitro

Dexrazoxane (0-500 μM; 0-24 h) induces DNA breaks, ATF3 accumulation, DNA damage response and apoptosis in human fibrosarcoma cell line [4].
Dexrazoxane(100 µM; 72 h) inhibits ferroptosis of H9c2 cells by inhibiting HMGB1[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dexrazoxane Related Antibodies

Western Blot Analysis[4]

Cell Line: Topoisomerase IIα-expressing HTETOP cells (HTETOP cells were derived from the human fibrosarcoma cell line HT1080 through the deletion of both endogenous topoisomerase IIα alleles and the insertion of a tetracycline-repressible topoisomerase IIα transgene)
Concentration: 100 μM
Incubation Time: 4 h
Result: Increased the phosphorylation level of Chk1, Chk2, ATR, and ATM.

Western Blot Analysis[4]

Cell Line: HTETOP cells
Concentration: 0, 10,100 and 500 μM
Incubation Time: 0, 1, 4, 8 and 24 h
Result: Increased AFT3 protein levels in a concentration-dependent and incubation time-dependent manner.

Western Blot Analysis[4]

Cell Line: Topoisomerase IIα-expressing HTETOP cells
Concentration: 100 μM
Incubation Time: 24 h
Result: Increased the expression level of P53.

Western Blot Analysis[5]

Cell Line: Doxorubicin (HY-15142) treated H9c2 cells
Concentration: 100 μM
Incubation Time: 72 h
Result: Decreased the expression level of HMGB1 protein.
In Vivo

Dexrazoxane (8 mg/kg; Intravenous injection; 7 weeks) plays a protective role in rat models of cardiomyopathy induced by doxorubicin (HY-15142)[2].
Dexrazoxane (5-15 mg/kg; Intraperitoneal injection; 3-5 weeks) has antioxidant and anti-inflammatory effects in rodent models of Parkinson's disease[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Doxorubicin (HY-15142) treated Wistar rats aged 11 weeks old[2]
Dosage: 8 mg/kg
Administration: Intravenous injection (i.v.); weekly for 7 weeks
Result: Reversed the respiratory or hepatic pathology caused by doxorubicin.
Enhanced cytochrome c-oxidase activity.
Decreased myocardial ROS levels.
Reversed the mitochondrial DNA deletion caused by doxorubicin.
Animal Model: 6-OHDA (HY-B1081) treated Sprague Dawley rats (180-220 g);
MPTP ( HY-15608 ) and probenecid (HY-B0545) treated mice aged 10 weeks old[6]
Dosage: 5 and 15 mg/kg;
10 mg/kg
Administration: Intraperitoneal injection (i.p.); 3 weeks
Intraperitoneal injection (i.p.); 5 weeks
Result: Attenuated neurotoxin-induced oxidative damage in serum, midbrain and striatum.
Suppressed neurotoxin-induced systemic inflammation in both of serum and midbrain.
Ameliorated neurotoxin-induced ER stress in midbrain.
Clinical Trial
Molecular Weight

268.27

Formula

C11H16N4O4
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (93.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7276 mL 18.6379 mL 37.2759 mL
5 mM 0.7455 mL 3.7276 mL 7.4552 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  15% Cremophor EL    85% Saline

    Solubility: 6.67 mg/mL (24.86 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.88%

SDS (393 KB)

COA (247 KB) LCMS (87 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.7276 mL 18.6379 mL 37.2759 mL 93.1897 mL
5 mM 0.7455 mL 3.7276 mL 7.4552 mL 18.6379 mL
10 mM 0.3728 mL 1.8638 mL 3.7276 mL 9.3190 mL
15 mM 0.2485 mL 1.2425 mL 2.4851 mL 6.2126 mL
20 mM 0.1864 mL 0.9319 mL 1.8638 mL 4.6595 mL
25 mM 0.1491 mL 0.7455 mL 1.4910 mL 3.7276 mL
30 mM 0.1243 mL 0.6213 mL 1.2425 mL 3.1063 mL
40 mM 0.0932 mL 0.4659 mL 0.9319 mL 2.3297 mL
50 mM 0.0746 mL 0.3728 mL 0.7455 mL 1.8638 mL
60 mM 0.0621 mL 0.3106 mL 0.6213 mL 1.5532 mL
80 mM 0.0466 mL 0.2330 mL 0.4659 mL 1.1649 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Dexrazoxane Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Dexrazoxane24584-09-6ICRF-187 ADR-529 NSC-169780ICRF187ICRF 187ADR529ADR 529ADR-529NSC169780NSC 169780NSC-169780FerroptosisApoptosisIron chelating agentCardioprotective agentHT1080 cellsParkinson modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dexrazoxane
Cat. No.:
HY-B0581
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.